WOBURN, Mass., April 30, 2025
Rgenta Therapeutics Announces Presentation of Preclinical Data from Proprietary RSwitch Technology at the American Society of Gene And Cell Therapy (ASGCT) 2025 Annual Meeting

Learn More

WOBURN, Mass., April 25, 2025
Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and Synergistic Activity when Combined with Standard of Care for AML

Learn More

WOBURN, Mass., March 25, 2025
Rgenta Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Learn More

WOBURN, Mass., Dec. 9, 2024
Rgenta Therapeutics Presents Preclinical Data Demonstrating Anti-Tumor Activity of Oral Small Molecule MYB Inhibitor, RGT-61159, in Multiple Models of AML at the 66th American Society of Hematology (ASH) Annual Meeting

Learn More

WOBURN, Mass., Dec. 4, 2024
Rgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice Modulators

Learn More

WOBURN, Mass., November 5, 2024
Rgenta Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Learn More

WOBURN, Mass., October 8, 2024

Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

Learn More

WOBURN, Mass., July 10, 2024

Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

Learn More

CAMBRIDGE, Mass., May 31st, 2024

Rgenta Therapeutics Presents Pre-Clinical Data from Lead Program RGT-61159, a Potent Inhibitor of Oncogenic MYB Synthesis, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024)

Learn More

CAMBRIDGE, Mass., Jan. 30, 2024

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®

Learn More

Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca

Learn More

Lundbeck bulks up neuro portfolio with $10M Rgenta pact after ditching Alzheimer's drug

Learn More

Rgenta Therapeutics Announces the Successful Completion of Extension of Seed Financing

Learn More

Stifel 2025 Virtual Targeted Oncology Forum 

Simon Xi, Ph.D., Chief Executive Officer

Wednesday, April 9, 2025 

Click here for webcast >>

CAMBRIDGE, Mass., Feb 26th, 2024
Rgenta Therapeutics to Participate Upcoming TD Cowen 44th Annual Health Care Conference (March 4th 2024)